Institution · Vir Biotechnology (Switzerland)

Most cited papers from Vir Biotechnology (Switzerland)

Vir Biotechnology (Switzerland)

What are the most cited papers from Vir Biotechnology (Switzerland)?

The most cited paper from Vir Biotechnology (Switzerland) is "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody" (Dora Pinto et al., 2020), with 2,164 citations. Next come "Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology" (1,646) and "SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion" (1,429).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 59 papers. Every paper with more than 153 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody Dora Pinto et al. · Nature Open access	18 May 2020	2,164
2	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology Luca Piccoli et al. · Cell Open access	16 Sep 2020	1,646
3	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion Petra Mlčochová et al. · Nature Open access261 authors	6 Sep 2021	1,429
4	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift Elisabetta Cameroni et al. · Nature Open access	23 Dec 2021	1,212
5	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity Bo Meng et al. · Nature Open access222 authors	Feb 2022	1,189
6	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 Matthew McCallum et al. · Cell Open access	18 Mar 2021	1,027
7	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies Rita E. Chen et al. · Nature Medicine Open access	4 Mar 2021	1,018
8	Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection Karin Stettler et al. · Science	14 Jul 2016	797
9	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies Laura A. VanBlargan, John M. Errico, Peter Halfmann et al. · Nature Medicine Open access	19 Jan 2022	772
10	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies Dami A. Collier et al. · Nature Open access1,136 authors	11 Mar 2021	717
11	Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion Alexandra C. Walls, Xiaoli Xiong, Young‐Jun Park et al. · Cell Open access	31 Jan 2019	692
12	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity Emma C. Thomson et al. · Cell Open access	28 Jan 2021	660
13	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms M. Alejandra Tortorici et al. · Science Open access	24 Sep 2020	631
14	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape Tyler N. Starr et al. · Nature Open access	14 Jul 2021	603
15	Bone grafts: which is the ideal biomaterial? Håvard Jostein Haugen, Ståle Petter Lyngstadaas, Filippo Rossi et al. · Journal Of Clinical Periodontology Open access	9 Jan 2019	581
16	Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement Matthew McCallum, Nadine Czudnochowski, Laura E. Rosen et al. · Science Open access	24 Feb 2022	576
17	A perspective on potential antibody-dependent enhancement of SARS-CoV-2 Ann M. Arvin, Katja Fink, Michael Schmid et al. · Nature Open access	13 Jul 2020	543
18	Broadly Neutralizing Antiviral Antibodies Davide Corti, Antonio Lanzavecchia · Annual Review of Immunology Review	19 Jan 2013	491
19	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2 James Brett Case et al. · Cell Host & Microbe Open access	2 Jul 2020	489
20	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern Matthew McCallum et al. · Science Open access	Jul 2021	465
21	Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes Nicole L. Kallewaard et al. · Cell Open access	Jul 2016	459
22	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020 Emma B. Hodcroft et al. · Nature Open access194 authors	7 Jun 2021	458
23	Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7 Bo Meng et al. · Cell Reports Open access882 authors	Jun 2021	454
24	After the pandemic: perspectives on the future trajectory of COVID-19 Amalio Telenti, Ann M. Arvin, Lawrence Corey et al. · Nature Open access	8 Jul 2021	449
25	Broad betacoronavirus neutralization by a stem helix–specific human antibody Dora Pinto et al. · Science Open access	3 Aug 2021	445
26	High-avidity IgA protects the intestine by enchaining growing bacteria Kathrin Moor et al. · Nature	Apr 2017	437
27	Tackling COVID-19 with neutralizing monoclonal antibodies Davide Corti, Lisa A. Purcell, Gyorgy Snell et al. · Cell Open access	26 May 2021	422
28	Two Waves of Nuclear Factor κb Recruitment to Target Promoters Simona Saccani, Serafino Pantano, Gioacchino Natoli · The Journal of Experimental Medicine Open access	11 Jun 2001	387
29	Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020 Emma B. Hodcroft, Moira Zuber, Sarah Nadeau et al. · medRxiv PreprintOpen access	28 Oct 2020	361
30	Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution Tyler N. Starr, Allison J. Greaney, William W. Hannon et al. · Science Open access	28 Jun 2022	349
31	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors Tongqing Zhou et al. · Cell Open access	21 May 2015	344
32	Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies Florian A. Lempp et al. · Nature Open access	31 Aug 2021	329
33	Rapid development of broadly influenza neutralizing antibodies through redundant mutations Leontios Pappas, Mathilde Foglierini, Luca Piccoli et al. · Nature	3 Oct 2014	323
34	Broad sarbecovirus neutralization by a human monoclonal antibody M. Alejandra Tortorici et al. · Nature Open access	19 Jul 2021	320
35	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants Matthew McCallum, Alexandra C. Walls, Kaitlin R. Sprouse et al. · Science Open access	23 Dec 2021	317
36	Cross-neutralization of four paramyxoviruses by a human monoclonal antibody Davide Corti, Siro Bianchi, Fabrizia Vanzetta et al. · Nature	16 Aug 2013	290
37	Immunogenetic Mechanisms Driving Norovirus GII.4 Antigenic Variation Lisa C. Lindesmith, Martina Beltramello, Eric Donaldson et al. · PLoS Pathogens Open access	17 May 2012	269
38	Imprinted antibody responses against SARS-CoV-2 Omicron sublineages Young‐Jun Park et al. · Science Open access	20 Oct 2022	267
39	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains Rita E. Chen et al. · Nature Open access	21 Jun 2021	261
40	The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2 Andrea L. Cathcart et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access	10 Mar 2021	255
41	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses Alexandra C. Walls, Kaitlin R. Sprouse, John E. Bowen et al. · Cell Open access	19 Jan 2022	224
42	Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70 Steven A. Kemp et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access	14 Dec 2020	224
43	Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation Matthew McCallum, Alexandra C. Walls, John E. Bowen et al. · Nature Structural & Molecular Biology Open access	4 Aug 2020	201
44	Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines John E. Bowen et al. · Science Open access	19 Jul 2022	198
45	IL-12 protects from psoriasiform skin inflammation Paulina Kulig, Stephanie Musiol, Sandra Nicole Freiberger et al. · Nature Communications Open access	28 Nov 2016	196
46	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines Alexandra C. Walls et al. · Cell Open access	15 Sep 2021	195
47	ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies Jun Siong Low et al. · Science Open access	12 Jul 2022	192
48	Platelet-derived growth factor-α receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer Anna Kabanova, Jessica Marcandalli, Tongqing Zhou et al. · Nature Microbiology Open access	6 Jun 2016	187
49	Neutralization, effector function and immune imprinting of Omicron variants Amin Mohamed G. Addetia et al. · Nature Open access	30 Aug 2023	184
50	A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens Joshua Tan et al. · Nature Open access	23 Dec 2015	178

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.